Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Common Equity data on record, last reported at $305.3 million in Q4 2025.

  • For Q4 2025, Common Equity rose 85.27% year-over-year to $305.3 million; the TTM value through Dec 2025 reached $305.3 million, up 85.27%, while the annual FY2025 figure was $305.3 million, 85.27% up from the prior year.
  • Common Equity reached $305.3 million in Q4 2025 per AMLX's latest filing, down from $332.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $433.4 million in Q4 2023 and bottomed at -$151.2 million in Q4 2021.
  • Average Common Equity over 5 years is $200.2 million, with a median of $221.2 million recorded in 2022.
  • Peak YoY movement for Common Equity: soared 398.83% in 2022, then plummeted 61.99% in 2024.
  • A 5-year view of Common Equity shows it stood at -$151.2 million in 2021, then soared by 325.32% to $340.6 million in 2022, then grew by 27.25% to $433.4 million in 2023, then tumbled by 61.99% to $164.8 million in 2024, then skyrocketed by 85.27% to $305.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $305.3 million in Q4 2025, $332.0 million in Q3 2025, and $167.9 million in Q2 2025.